Mostrando 10 resultados de: 13
Filtros aplicados
Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusA metabolic perspective of late onset Alzheimer's disease
ReviewAbstract: After decades of research, the molecular neuropathology of Alzheimer's disease (AD)is still one of tPalabras claves:Alzheimer's disease, c-Jun N-terminal kinase inhibitors, Insulin, Licochalcone A, neuroinflammation, Reticulum stress, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E., Zárate C.B.Fuentes:scopusADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
ReviewAbstract: Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-Palabras claves:ADAM10, Alzheimer's disease, Natural compounds, Pharmaceutical, α-SecretaseAutores:Antoni Camins, Busquets O., Cano A., Cominetti M.R., Di Luca M., Endres K., Ettcheto M., Manzine P.R., Marcello E., Olloquequi J., Pelucchi S.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusAlpha-secretase ADAM10 regulation: Insights into Alzheimer’s disease treatment
ReviewAbstract: ADAM (a disintegrin and metalloproteinase) is a family of widely expressed, transmembrane and secretPalabras claves:ADAM10, Alzheimer’s disease, regulation, TreatmentAutores:Antoni Camins, Cominetti M.R., Manzine P.R., Peron R., Vatanabe I.P.Fuentes:scopusEpigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice
ArticleAbstract: Epigallocatechin-3-gallate (EGCG), a catechin found in green tea, has been previously investigated fPalabras claves:APPswe/PS1dE9 mice, Cognitive deficits, Epigallocatechin-3-gallate, hippocampus, obesity, unfolded protein responseAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Verdaguer E., Zárate C.B.Fuentes:scopusMetformin a potential pharmacological strategy in late onset Alzheimer’s disease treatment
ReviewAbstract: Alzheimer’s disease (AD) is one of the most devastating brain disorders. Currently, there are no effPalabras claves:Alzheimer’s disease, AMP activated protein kinase AMPK, Beta amyloid, diabetes mellitus, Insulin Resistance, Metformin, Tau protein hyperphosphorylationAutores:Antoni Camins, Cano A., Ettcheto M., Javan M., Manzine P.R., Olloquequi J., Poor S.R., Sanchez-Lopez E.Fuentes:scopusPharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease
ReviewAbstract: To deeply understand late onset Alzheimer's disease (LOAD), it may be necessary to change the concepPalabras claves:BDNF, dendritic spines, late onset Alzheimer's disease, neuroinflammation, obesity, Type 2 Diabetes mellitusAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Casadesús G., Castro-Torres R.D., Espinosa-Jimenez T., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Sureda F.X., Verdaguer E.Fuentes:scopusTriple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer’s disease
ArticleAbstract:Palabras claves:Alzheimer’s disease, glucagon, glucagon-like peptide, glucose-dependent insulinotropic peptide, Type 2 DiabetesAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Castro-Torres R.D., Ettcheto M., Folch J., Manzine P.R., Olloquequi J., Sureda F.X., Verdaguer E., Zárate C.B.Fuentes:scopusRole of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model
ArticleAbstract: Insulin resistance has negative consequences on the physiological functioning of the nervous system.Palabras claves:ER stress, high-fat diet, JNK, metabolism, neuroinflammation, PTP1BAutores:Antoni Camins, Auladell C., Busquets O., Castro-Torres R.D., Eritja À., Ettcheto M., Folch J., López B.M., Manzine P.R., Olloquequi J., Vázquez-Carrera M., Verdaguer E.Fuentes:scopus